SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally

SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally

By: IPP Bureau

Last updated : July 17, 2025 10:53 am



The receipt of EIR reaffirms the company's commitment to maintaining global quality standards


SMS Lifesciences India Limited has received Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration for our API manufacturing facility (Unit 1) located at Kazipally, Telangana.

The receipt of EIR reaffirms the company's commitment to maintaining global quality standards and enables access to the regulated US market and other highly regulated global markets.

SMS Lifesciences India USFDA

First Published : July 17, 2025 12:00 am